Your browser doesn't support javascript.
loading
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant dependent manner
Roanne Keeton; Simone I Richardson; Thandeka Moyo-Gwete; Tandile Hermanus; Marius B Tincho; Ntombi Benede; Nelia P Manamela; Richard Baguma; Zanele Makhado; Amkele Ngomti; Thopisang Motlou; Mathilda Mennen; Lionel Chinoyi; Sango Skelem; Hazel Maboreke; Deelan Doolabh; Arash Iranzadeh; Ashley D Otter; Tim Brooks; Mahdad Noursadeghi; James Moon; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Jonathan Blackburn; Nei-Yuan Hsiao; Carolyn Williamson; Catherine Riou; Ameena Goga; Nigel Garrett; Linda-Gail Bekker; Glenda Gray; Ntobeko A.B Ntusi; Penny L Moore; Wendy A Burgers.
Affiliation
  • Roanne Keeton; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Simone I Richardson; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Thandeka Moyo-Gwete; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Tandile Hermanus; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Marius B Tincho; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Ntombi Benede; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Nelia P Manamela; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Richard Baguma; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Zanele Makhado; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Amkele Ngomti; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Thopisang Motlou; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Mathilda Mennen; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Lionel Chinoyi; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Sango Skelem; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Hazel Maboreke; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Deelan Doolabh; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Arash Iranzadeh; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Ashley D Otter; National Infection Service, Public Health England, Porton Down, UK
  • Tim Brooks; National Infection Service, Public Health England, Porton Down, UK
  • Mahdad Noursadeghi; University College London
  • James Moon; Institute of Cardiovascular Sciences, University College London, London
  • Alba Grifoni; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
  • Daniela Weiskopf; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
  • Alessandro Sette; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
  • Jonathan Blackburn; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Nei-Yuan Hsiao; Division of Medical Virology, Department of Pathology, University of Cape Town; Observatory, South Africa
  • Carolyn Williamson; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Catherine Riou; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Ameena Goga; South African Medical Research Council, Cape Town, South Africa.
  • Nigel Garrett; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
  • Linda-Gail Bekker; Desmond Tutu HIV Centre, Cape Town, South Africa
  • Glenda Gray; South African Medical Research Council, Cape Town, South Africa.
  • Ntobeko A.B Ntusi; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
  • Penny L Moore; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
  • Wendy A Burgers; Institute of Infectious Disease and Molecular Medicine University of Cape Town, Observatory, South Africa
Preprint in En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21261037
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
The Johnson and Johnson Ad26.COV2.S single dose vaccine represents an attractive option for COVID-19 vaccination in resource limited countries. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared participants who were SARS-CoV-2 naive with those either infected with the ancestral D614G virus, or infected in the second wave when Beta predominated. Prior infection significantly boosted spike binding antibodies, antibody-dependent cellular cytotoxicity and neutralizing antibodies against D614G, Beta and Delta, however neutralization cross-reactivity varied by wave. Robust CD4 and CD8 T cell responses were induced after vaccination, regardless of prior infection. T cell recognition of variants was largely preserved, apart from some reduction in CD8 recognition of Delta. Thus, Ad26.COV2.S vaccination following infection may result in enhanced protection against COVID-19. The impact of the infecting variant on neutralization breadth after vaccination has implications for the design of second-generation vaccines based on variants of concern.
License
cc_by
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Rct Language: En Year: 2021 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Rct Language: En Year: 2021 Document type: Preprint